Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rapid-Seal
- Development stage
- Unknown
- Lead developer
- Medcura
- Administration
- Topical
01
Overview
Rapid-Seal is a topical bleeding-control and wound-management product developed by Medcura for minor cuts and scrapes. It is an antibacterial gel based on a proprietary modified chitosan biopolymer, designed to rapidly form a seal over superficial wounds, promote hemostasis within seconds, and inhibit bacterial growth at the wound surface. The product appears to function primarily through the physical and bioactive properties of modified chitosan rather than through a defined receptor-mediated pharmacology, and it has been described as a commercially available consumer product with FDA clearance for related advanced bandage use in prescription and over-the-counter settings.
- Brand names
- Rapid-Seal
- Other names
- Rapid-Seal
Beyond the preview
Go deeper on Rapid-Seal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rapid-Seal.